Bad news for expansion classes

The FDA decided to do an advisory committee meeting because the indication is so large. Based on when Amarin submitted the supplemental new drug application, the Advisory Committee should have been scheduled in August. Instead the FDA scheduled it in November. It will all work out in the end. It is a very safe and effective drug that is already changing the way cardiologist and endocrinologist practice. The ADA has already changed their guidelines for diabetics. Good luck with your interviews and hiring. Patience with this company and the hiring process will pay off.

 

Great drug. Easy to sell. However, expect after the new year to be sold to big pharma and displaced!